Drugs / Radium-223
Radium-223
also known as
223Ra · Radium-223 dichloride · BAY88-8223 · Ra223 · Radium Ra 223 dichloride · Xofigo
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03208712 | Nov 2017 → Aug 2018 | urothelial carcinoma | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 14 trials | ||||||
| Phase 1 | NCT04521361 | Nov 2020 → Oct 2023 | prostate carcinoma | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04109729 | Sep 2020 → Apr 2026 overdue | castration-resistant prostate carcinoma | University of Utah | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02406521 | Apr 2015 → Dec 2017 | renal cell carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02396368 | Mar 2015 → Jul 2017 | prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05383079 | Sep 2022 → Aug 2026 overdue | prostate carcinoma | Peter MacCallum Cancer Centre, Australia | Active not recruiting | No outcome recorded |
| Phase 210 trials · 2 missed | ||||||
| Phase 2 | NCT05924672 | Aug 2024 → Jan 2026 overdue | castration-resistant prostate carcinoma, metastatic carcinoma in the bone | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04704505 | Apr 2022 → Feb 2028 expected | castration-resistant prostate carcinoma, prostate adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT04206319 | Sep 2020 → Feb 2026 overdue | prostate carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04037358 | Aug 2019 → Jul 2025 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | Missed primary |
| Phase 2 | NCT03230734 | Sep 2017 → Jul 2025 overdue | castration-resistant prostate carcinoma | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03093428 | Jun 2017 → Apr 2020 | prostate cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT03002220 | Dec 2016 → May 2020 | prostate cancer | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT02463799 | Feb 2016 → Dec 2019 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | Missed primary |
| Phase 2 | NCT02225704 | Jun 2015 → Jul 2017 | prostate cancer | Cancer Trials Ireland | Completed | No outcome recorded |
| Phase 2 | NCT02278055 | Oct 2014 → Feb 2022 | metastatic prostate carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05771896 | Sep 2023 → Dec 2028 | metastatic prostate carcinoma | GenesisCare USA | Withdrawn | No outcome recorded |
| Phase 3 | NCT03574571 | Jun 2018 → Apr 2027 expected | prostate cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02135484 | Sep 2014 → Nov 2020 | prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 0 | NCT02204943 Background | May 2015 → Jul 2017 | castration-resistant prostate carcinoma | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT07611110 Comparator | May 2026 → Feb 2029 expected | prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT04237584 Comparator | Jun 2020 → Mar 2022 | castration-resistant prostate carcinoma | MANA RBM | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03432949 Background | Feb 2018 → Sep 2023 | metastatic prostate carcinoma | University Health Network, Toronto | Unknown | No outcome recorded |
Press releases naming this drug 3 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Radium-223 | “The goal of this clinical research study is to learn more about how the study drug alpharadin (Radium-223) works in patients who have CPRC that has spread to the bone.” NCT02135484 ↗22“Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8.” NCT02396368 ↗ “Radium-223 is an alpha-particle-emitting bone-targeted therapy.” NCT04704505 ↗ |
| Known as | 223Ra | “Lutetium-177 [177Lu]Lu-PSMA-I&T (177Lu-PSMA-I&T) and the bone-seeking α-emitter radium-223 (223Ra) are established life-extending therapies” PMID 41119954 ↗ Oct 20251“up to six doses of 223Ra (55 kBq/kg of body weight per month)” PMID 35981452 ↗ Aug 2022 |
| Known as | BAY88-8223 | “Radium-223 dichloride (Xofigo, BAY88-8223)” NCT04521361 ↗ |
| Known as | Ra223 | “We hypothesized the BM-targeting alpha-emitter radium-223 dichloride (Ra223) could target subclinical bone disease and delay progression.” PMID 40334149 ↗ May 2025 |
| Known as | Radium Ra 223 dichloride | “Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug.” NCT02396368 ↗ |
| Known as | Radium-223 dichloride | “Radium-223 dichloride is a radiopharmaceutical with structural similarity to calcium, allowing it to be taken up by bone where it emits alpha particles, and therefore might...” PMID 32487038 ↗ Jun 20201“Radium-223 dichloride (Xofigo, BAY88-8223)” NCT04521361 ↗ |
| Known as | Xofigo | “Radium-223 dichloride (Xofigo, BAY88-8223)” NCT04521361 ↗ |
| Modality | Other / unclassified | “Targeting PCa-induced bone with the radiopharmaceutical Radium-223 (Ra223) is approved for men with bone-metastatic castration-resistant PCa (bmCRPC).” PMID 41454189 ↗ Dec 2025 |
| Route | Intravenous | “administered by slow intravenous injection” NCT02135484 ↗ |